Injection of naked DNA in muscle results in transfection of cells in vivo
Gene therapy would be a lot simpler if we could forget about recombinant viruses or complexing DNA with polymers or lipids. It has been known for years that naked DNA can be delivered to cells in vivo and result in gene expression. However, the efficiency of gene transfer into skeletal or cardiac muscle is relatively low and variable. Attempts to increase pDNA uptake, for instance by inducing muscle regeneration, have not increased efficiency to a level that would allow for clinical use in gene therapy protocols. As a result, naked DNA gene transfer has been mainly used for genetic immunization studies. In recent years, work in several laboratories has shown that naked plasmid DNA (pDNA) can be delivered efficiently to cells in vivo either via electroporation, or by intravascular delivery, and has great prospects for basic research and gene therapy.
Electroporation enhances uptake of injected plasmid DNA into muscle and skin
The last few years has seen a marked increase in the number of studies employing intramuscular or intrader-
In brief Progress
* Injection of naked DNA in muscle results in transfection of cells in vivo. * Electroporation enhances uptake of injected plasmid DNA into muscle and skin. * Intravascular delivery of plasmid DNA results in a very effective gene transfer of hepatocytes. * Tail vein pDNA delivery is a simple and effective method for transfecting liver cells in mice and rats. * Effective transfection of skeletal muscle cells in mice, rats, dogs, and monkeys via intravascular delivery of plasmid DNA. * Novel pDNA expression vectors allow for high-level sustained expression. * The mechanism of intravascular naked DNA delivery is thought to involve active cellular pDNA uptake. * Naked DNA delivery has entered clinical studies for peripheral arterial occlusion disease (PAOD).
* Small interfering RNA (siRNA) can be delivered very efficiently using intravascular gene transfer methods and results in potent knock out of the target gene expression.
Prospects
* Nonviral gene transfer will become more important as better delivery methods become available. * Clinical trials for genetic diseases (eg, Duchenne muscular dystrophy, ischemia, hemophilia) will be initiated in the next few years. * Tail vein injections in rodents will become a widely used technique for rapidly testing expression vectors and gene therapy approaches. * RNA interference will become a major element in the gene therapy field.
mal injection of naked DNA followed by electroporation. Technical improvements in electroporation equipment made in recent years, as well as better methodology following years of experimentation, have enabled increases both in gene transfer efficiency and safety. 1 A very large number of publications in the last few years have demonstrated gene transfer to a variety of different cell types in vivo. Expression levels in muscle are at least 10-fold higher compared to injection of pDNA without electroporation, but are accompanied by elevation of serum creatine kinase levels. 2 It is not clear whether these increases in transgene expression (especially of secreted proteins) are due to enhanced gene transfer into myofibers, or to simultaneous transfer into different cell types (eg, endothelial cells). Expression levels are considered sufficient to warrant further investigation of this method for gene therapy, for instance for chronic anemia 3 or muscular dystrophies. 4 Yet, expression levels are not as high as those achieved following intravascular delivery, 5 (see below). Injection of naked DNA in conjunction with electroporation into skeletal muscle or skin should enhance the efficacy of genetic immunization procedures. 6 Intravascular delivery of plasmid DNA results in very effective gene transfer of hepatocytes Intravascular delivery of genes is attractive because it avoids the necessity for multiple intraparenchymal injections into the target tissue. The gene is disseminated throughout the tissue since the vascular system accesses every cell. Vascular delivery could be systemic or regional in which injections are into specific vessels that supply a target tissue. 7 The intravascular delivery of adenoviruses or cationic lipid-DNA complexes in adult animals mostly results in expression in vascular-accessible cells such as endothelial cells or hepatocytes reached via the sinusoid fenestrae. Efficient transgene expression in hepatocytes throughout the liver can be obtained following delivery of naked pDNA via the portal vein, the hepatic vein, or the bile duct in mice and rats. The use of hyperosmotic injection solutions and occlusion of the blood outflow from the liver substantially increased the expression levels, although it was later shown that a hyperosmotic solution is not absolutely necessary.
Tail vein pDNA delivery is a simple and effective method for transfecting liver cells in mice and rats A major advance in the intravascular delivery of pDNA was the recent development of the tail vein delivery procedure in the Wolff and Liu laboratories. As a logical extension to rapid delivery of a relatively large volume into a vessel leading into or from the liver, the tail vein itself can be employed. The tail vein drains into the vena cava. Delivery of a large bolus presumably results in a liquid volume in the vena cava that is too large for the heart to handle rapidly. The fluids back up and end up (predominantly) in the liver, resulting in gene transfer. This explains the rather delicate sensitivity of this method of gene delivery upon delivery volume and speed. Several groups have found that the optimal volume is around 10% of the body weight of a mouse or rat. 7.8 The delivery time should be between 5 and 7 s in mouse; 15-20 s in rat, these times being the fastest rates that can be practically achieved by skilled operators.
Tail vein or hydrodynamic delivery results in very high levels of gene transfer. Typically, 10-15% of the hepatocytes are transfected in mouse liver following injection of 10 mg pDNA, but levels up to 40% have been reported. We have measured high levels of reporter genes (about 2 mg luciferase, 50 mg secreted alkaline phosphatase) and supranormal levels of therapeutic genes (55 mg/ml human factor IX, 1.6 mg/ml human factor VIII, 915 ng/ml rhesus erythropoietin) one day after gene delivery. Transgene expression is also found in heart, spleen, and kidneys, at levels about 100-fold lower than in liver. While the procedure seem harsh, nearly all animals survive (99%) and show no ill effects. Liver enzymes are transiently elevated. For instance, we observed serum alanine aminotransaminase (ALT) levels around 1000 U/ml 24 h after injection in mice. The ALT levels diminished to normal over the next few days. Liver histology shows minimal damage that resolves within a week, which is similar to the data we observed for intravascular delivery into liver vessels. 9 The tail vein method has been adopted remarkably quickly in the gene therapy field for basic research and gene therapy evaluation. At the recent meeting of the American Society of Gene Therapy (June 5-9, 2002), 22 abstracts were presented employing this novel technique. Owing to its simplicity and reproducibility, it allows for the rapid testing of novel expression vectors (whether or not the expression cassette will eventually be used in a viral or a nonviral vector). We, and others, have used tail vein injections to evaluate the expression cassettes capable of driving sustained high level expression in the liver. [9] [10] [11] [12] [13] [14] As it is easy to regulate the level of gene expression by adjusting the amount of plasmid DNA, it is now possible to test accurately the level of transgene expression required for achieving a physiological effect in a disease model (eg, the level of phenylalanine hydroxylase (PAH) expression in PAH-deficient phenylketonurea (PKU) mice; Cary Harding, personal communication).
As the liver is the organ that is predominantly transfected, testing gene therapy approaches may be limited to those diseases where liver transgene expression is appropriate. However, the liver may be used as an ectopic expression site for secreted proteins (eg, erythropoietin), or in a situation where hepatocytes can take over the function of other cells (eg, as in clearing of metabolites). An often asked question is how this technique can be translated to the human situation. Since the human tail is on the short side, other entry points need to be found. We have extensively investigated intravascular delivery to the liver in large animals (unpublished data). It appears that similar efficiencies can be obtained in monkeys as in mice by injecting pDNA into the afferent or efferent vessel of the liver. Such injections can be done via catheters in humans, making this a relatively simple procedure. Eastman et al 15 recently presented data in rabbits, reporting high expression levels following delivery of pDNA via balloon occlusion catheters introduced into the portal vein. Effective transfection of skeletal muscle cells in mice, rats, dogs, and monkeys via intravascular delivery of plasmid DNA
The intravascular delivery of naked pDNA to muscle cells is also attractive particularly since many muscle groups would have to be targeted for intrinsic muscle disorders such as Duchenne muscular dystrophy. An intravascular approach would avoid the limited distribution of pDNA through the interstitial space following intramuscular injection. Muscle has a high density of capillaries that are in close contact with the myofibers. Delivery of pDNA to muscle via capillaries puts the pDNA into direct contact with every myofiber and substantially decreases the interstitial space the pDNA has to traverse in order to access a myofiber. However, the endothelium in muscle capillaries is of the continuous, nonfenestrated type and has low solute permeability, especially to large macromolecules. Nonetheless, rapid delivery of relatively large volumes of pDNA solutions (10 ml injected into rat iliac artery) resulted in very efficient gene transfer into myofibers. With the best injection condition, up to 50% of myofibers expressed bgalactosidase in many areas of the muscles. Experiments have successfully been performed in mice, although these are technically difficult to do. Expression levels and percentage of transfected cells do vary significantly from mouse to mouse, yet up to 20% of transfected myofibers have been observed regularly. Studies in larger animals have now demonstrated the clinical relevance of this method of gene delivery. Intravascular delivery to limb skeletal muscle has successfully been performed in rabbits, dogs, and rhesus monkeys (Zhang et al 17 ; unpublished results). Several alternative methods for delivering the pDNA solution and blocking limb blood flow have been evaluated. Delivery via a catheter to regional target muscle groups, in combination with blocking blood flow with a tourniquet or blood pressure cuff, is very effective in larger animals. In rhesus monkeys, transfection efficiencies of 40% have been observed, 17 a number that is considered sufficient for treatment of muscle defects such as Duchenne muscular dystrophy. A transient increase in serum creatine kinase levels was measured, which resolved within a few days. The short time required for occluding blood flow to skeletal muscle should be well tolerated in a human clinical setting since ischemia can be tolerated by muscles for 2-3 h. In fact, a common anesthetic procedure for distal limb surgery (eg, carpal tunnel repair) involves the placement of a tourniquet to block both venous and arterial blood flow and the intravenous administration of a local anesthetic (eg, lidocaine) distal to the tourniquet. Surgery in humans can be performed for a couple of hours using these anesthetic procedure. Similarly, histologic analyses of the rat, dog, and rhesus muscles in our experiments indicated that the ischemia did not cause myofiber damage. Besides gene therapy for muscle defects, it appears worthwhile to evaluate this method for delivery of angiogenic genes for the treatment of ischemia. Delivery is not limited to skeletal muscle, but can also target cardiac muscle (retrograde delivery via standard angioplasty catheters) and can thus potentially be used for treating heart ischemia. 18 Novel pDNA expression vectors allow for high level sustained expression
One of the problem areas in gene therapy is the sustained expression of transgenes at high levels. We have recently analyzed five explanations for the rapid loss of expression observed after intravascular pDNA gene delivery to the liver. 9 While these analyses were performed following portal vein delivery, the conclusions appear valid for other intravascular delivery routes to the liver. First, the injection procedure or the presence of intracellular pDNA may induce cell death causing loss of the vector. As described above, it is clear that the injection procedure (with pDNA or with vehicle alone) does induce damage. But, all pathological reactions observed were transient and liver morphology was restored at day 4 after manipulation.
Second, intravascular delivery of pDNA may result in increased cell cycling causing the loss of the nonintegrated pDNA. While an increase in the number of cycling cells was found (BrdU labeling studies), peaking at 2 days at 1-1.5%, cycling appears to be insufficient to fully account for the 5000-fold drop in expression observed for CMV promoter-driven luciferase expression (day 1 to day 7). Third, pDNA may be lost independent of cell replication. Southern blotting experiments allowed us to determine the time course of pDNA loss. pDNA is rapidly lost in the first 24 h, likely reflecting the loss of extracellular pDNA or pDNA associated with Kupffer cells. 19 The decline in pDNA levels from day 1 to day 7 was 10-40 fold, much less than the loss of reporter gene expression in the same period (5000 fold).
Fourth, the promoter driving reporter gene expression may be inactivated, thus resulting in the loss of reporter gene expression. Comparison of viral-and tissue-specific promoters revealed that (1) viral promoters generally express at very high levels 1 day after injection; (2) viral promoter-driven reporter gene expression falls precipitously after day 1; (3) the liver-specific albumin promoter expresses at much lower levels on day 1, but expresses at a similar level on day 7. We therefore hypothesized that the enormous drop in expression measured for the viral promoters is the result of promoter inactivation. Fifth, the expressed proteins may induce an antigen-specific immune response, resulting in a further loss of expression after 2-3 weeks.
Our observations indicate that loss of transgene expression following pDNA gene transfer to the liver occurs in two phases. There is a rapid loss of expression in the first few days, followed by a slower decrease after about 1 week. The loss of expression in this latter phase appears to be the result of an antigen-specific immune response in normal, immunocompetent mice, as expresNaked DNA Gene Transfer and Therapy H Herweijer and JA Wolff sion is much prolonged in immunocompromised mice. The early phase of expression loss appears multifactorial. The delivery procedure does result in liver damage, as evidenced by histological observation and an increase in hepatocyte cell cycling. It is therefore likely that part of the transfected cells are destroyed, or nonintegrated plasmid DNA is lost during cell cycling. Overall, the loss of pDNA during this phase is not nearly as great as the loss of expression. Relatively sustained expression driven by the liver-specific albumin promoter (albeit at low levels) supports this hypothesis. This has recently been confirmed more conclusively by Miao et al, who described long-term expression of human factor IX in mice following tail vein injection of a plasmid DNA vector employing an a1-antitrypsin promoter in conjunction with a hepatic control region. 10, 11 Similar expression vectors with liver-specific promoters and transcriptional regulatory elements developed in our lab have corroborated these results.
It is now well established that certain sequences in bacterial DNA stimulate the immune system
.20 This appears to be based on the absence of CpG methylation in bacterial DNA, whereas in mammalian DNA most CpG sequences are methylated. By inclusion of these sequences in genetic vaccines, an enhanced immune response can be induced that is skewed to Th-1. 21 If the objective is long-term expression, minimizing the CpG content of the pDNA vector is beneficial. 13 Combination of liver-optimized expression cassettes in CpG-minimized vectors has made sustained, high-level transgene expression in the liver following naked pDNA delivery a reality.
The mechanism of intravascular naked DNA delivery is thought to involve active cellular pDNA uptake
The combined intraparenchymal and emerging intravascular data indicates that the uptake and expression of naked DNA is a general property of animal cells within a tissue architecture. It is common to cells of all three lineages: endoderm (eg, hepatocytes), mesoderm (eg, muscle), and ectoderm (eg, skin). This property is typically lost when the cells are removed and maintained in culture. Tissue disruption and cell isolation may modify the cell so that it can no longer take up naked DNA.
The intravascular injection conditions presumably enhance DNA transfer to hepatocytes by opening transiently the hepatic endothelial barrier. Under normal conditions, the B0.1 mm size of the fenestrae would prevent the exit from the sinusoids of plasmid DNA, has a gyration radius of B0.1 mm. Raising the intraportal pressure may transiently enlarge their size and thereby increase the extravasation of the pDNA complexes. In fact, results using fluorescent-labeled DNA showed that the increased pressure was required for movement of the DNA out of the sinusoids and to the hepatocytes. Several observations suggest that the mechanism of pDNA uptake may involve native cellular uptake processes. pDNA uptake was time-dependent, suggesting that it is due in part to a cellular process. 19 A receptor-mediated process is suggested by the inhibition of expression (from intramuscularly injected pDNA) by excess salmon sperm DNA, dextran sulfate, 19 or heparin. 22 These cellular processes may be aided or initiated by the rapid injection of the large volumes.
After traversing the plasma membrane, the pDNA must enter the nucleus since it is highly unlikely that plasmid DNA containing RNA polymerase II promoters could be expressed anywhere else. Although it is often assumed that DNA enters the nucleus from the cytoplasm little is known about the actual nuclear uptake process despite many advances toward an understanding of protein and RNA nuclear transport.
Our preliminary model of DNA nuclear uptake is as follows. After cytoplasmic delivery, the small amount of DNA that avoids binding to or sequestration by cytoplasmic elements enters the intact nucleus through the nuclear pore. The relatively rare entry of DNA into the nucleus (in comparison with karyophilic proteins) could be explained by its rapid and substantial cytoplasmic sequestration and its low rate of transport through the nuclear pore. This understanding of DNA nuclear transport provides a basis for future efforts to increase the efficiency of this process and is consistent with efforts to increase the amount of DNA delivered to the cytoplasm. For example, we have observed increased nuclear entry in digitonin-permeabilized cells of pDNA containing covalently attached SV40 T antigen nuclear localizing signal.
Naked DNA delivery has entered clinical studies for peripheral arterial occlusion disease (PAOD) Several studies have been initiated for the treatment of limb ischemia or PAOD, using direct injection of pDNA into skeletal muscle as the gene transfer method. While notoriously difficult to evaluate, a benefit was noted in several early-phase clinical studies. Simovic et al 23 performed a dose-escalation study in 29 patients with critical leg ischemia. After intramuscular injection of naked pDNA expressing the human vascular endothelial growth factor (VEGF) driven by a CMV promoter, patients had significant clinical improvements in examination scores and vascular ankle-brachial index in the treated limb. 23 This was accompanied with improvements in electrophysiologic measures 6 months after gene transfer. Similar results were reported by Comerota et al 24 in a trial involving FGF-1 gene transfer into 51 patients with lower leg ischemia. 24 A significant decrease in reported pain and ulcer size was observed, as well as an improved transcutaneous oxygen pressure and anklebrachial index. No increase in FGF-1 serum levels was measured, suggesting that localized expression may be effective. While clearly encouraging, the gene therapy clinical trials to date have been predominantly small and noncontrolled (open label). Initial results show encouraging improvements, although absolute increases in study parameters remain relatively small.
Several questions are in need of answering prior to entering large-scale clinical trials: (1) Which angiogenic gene, or cocktail of genes, should be used? VEGF and FGF-1 appeared to work in these early trials, but are likely not optimal factors. The basic biology of angiogen- Small interfering RNA (siRNA) can be delivered very efficiently using intravascular gene transfer methods and results in potent knockout of target gene expression RNA interference (RNAi) has been demonstrated to be highly effective for gene knockdown in a number of experimental organisms, as well as in mouse oocytes and preimplantation embryos. RNAi is mediated by doublestranded RNA (dsRNA), where mRNAs with sequence identity to the double-stranded RNA are degraded rapidly. It has been demonstrated using cultured mammalian cells that RNAi can be accomplished by delivering short interfering RNAs (siRNAs, dsRNA of 21-25 bp length), which circumvents the induction of an interferon response normally associated with the delivery of longer dsRNA. We and others have determined that siRNAs can be delivered to tissues in vivo by intravascular delivery. 25, 26 Expression of reporter genes (luciferase from codelivered pDNA or GFP in transgenic mice) and endogenous genes can be downregulated by 90% in a majority of liver cells following one injection with an appropriate siRNA. We have also observed efficient reporter gene downregulation in heart, lung, spleen, and other tissues following tail vein delivery in mice. It is likely that several hurdles, associated with gene delivery, are easier to overcome for siRNA delivery. siRNAs are much smaller than pDNA, and therefore vascular extravasation and cellular uptake may be easier. siRNAs exert their effect in the cytoplasm; therefore, the slow step of nuclear entry is avoided. It is not clear yet how long the RNAi effect lasts following delivery of a single dose of siRNA. Nonetheless, it appears that RNAi is becoming a very important extension of what we should call now the naked nucleic acid transfer field.
Summary
The direct intramuscular injection of naked DNA is in common use for genetic immunization and an HIV vaccine clinical trial is in progress. The efficiency of gene expression following the intravascular delivery of naked DNA is high in muscle and liver, even approaching what can be achieved with viral vectors. High expression is also possible in larger animals including primates and there are potential applications of the technique for treating human disorders. Given that tail vein injections of naked DNA under certain conditions lead to high levels of foreign gene expression in hepatocytes in rodents and is convenient, the technique is gaining increasing favor for studying gene expression in vivo. The technique also enables delivery of siRNA to the liver and other organs in mice and should be useful for attenuating gene expression.
